Comparative Evaluation of Atorvastatin 20 mg versus 40 mg in the Management of Primary Hypercholesterolemia
DOI:
https://doi.org/10.53350/pjmhs02025196.2%20Keywords:
Atorvastatin, hypercholesterolemia, LDL-C, statins, lipid profileAbstract
Background: Atorvastatin, a commonly prescribed statin, plays a central role in lowering low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. While the 20 mg and 40 mg doses are frequently used in clinical practice, comparative real-world data on their lipid-lowering efficacy and tolerability remains limited in the Pakistani population.
Objective: To evaluate and compare the efficacy and safety of Atorvastatin 20 mg versus 40 mg in managing primary hypercholesterolemia in adult patients at a tertiary care hospital in Lahore.
Methodology: This prospective, comparative clinical study was conducted at Jinnah Hospital, Lahore, from March 2023 to December 2023. A total of 100 adult patients diagnosed with primary hypercholesterolemia were enrolled and randomly assigned into two groups: Group A (n=50) received Atorvastatin 20 mg once daily, and Group B (n=50) received Atorvastatin 40 mg once daily. Baseline and 12-week follow-up lipid profiles (LDL-C, total cholesterol, HDL-C, and triglycerides) were recorded. Adverse effects and liver enzyme levels were monitored throughout the study.
Results: At the end of 12 weeks, Group B (40 mg) showed a statistically significant greater reduction in LDL-C and total cholesterol levels compared to Group A (20 mg) (p<0.05). HDL-C improved in both groups, while triglyceride reduction was more prominent in the higher dose group. No serious adverse events were reported; mild elevations in liver enzymes were noted in 4% of patients in Group B.
Conclusion: Atorvastatin 40 mg demonstrates superior lipid-lowering efficacy over 20 mg without a substantial increase in adverse effects, supporting its use in patients with higher cardiovascular risk profiles.
References
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92(2):152–60.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319(15):1566–79.
Reiner Ž. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2013;24(10):1057–66.
Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631.
Khan SU, Khan MU, Riaz H, Valavoor S, Zhao D, Vaughan L, et al. Effects of nutritional supplements and dietary interventions on cardiovascular outcomes: an umbrella review and evidence map. Ann Intern Med. 2019;171(3):190–8.
Javed Z, Maqsood MH, Yahya T, Amin Z, Acquah I, Valero-Elizondo J, et al. Race, racism, and cardiovascular health: applying a social determinants of health framework to racial/ethnic disparities in cardiovascular disease. Diabetes Care. 2022;45(Suppl 1):S17–S38.
Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. Indian Heart J. 2017;69(3):382–92.
Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51(6):1546–53.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.
Mahmood S, Naeem M, Raza H, Khan KS, Hassan A, Rahim M. Prevalence and pattern of dyslipidemia in hyperglycemic patients and its associated factors among Pakistani population. J Diabetes Metab Disord. 2021;20(1):399–406.
Oh PC, Jang AY, Ha K, Kim M, Moon J, Suh SY, et al. Effect of atorvastatin (10 mg) and ezetimibe (10 mg) combination compared to atorvastatin (40 mg) alone on coronary atherosclerosis. Am J Cardiol. 2021;154:22–8.
Ah YM, Jeong M, Choi HD. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: a meta-analysis of randomized controlled studies. PLoS One. 2022;17.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane; 2022.
Tanveer, M., et al. (2025). Effectiveness of a school-based physical activity intervention on overweight and obesity among children and adolescents in Pakistan. PLoS ONE, 20(2), e0317534. https://doi.org/10.1371/journal.pone.0317534
Tanveer, M., et al. (2025). Associations of 24-h movement behaviour with overweight and obesity among school-aged children and adolescents in Pakistan: An empirical cross-sectional study. Pediatric Obesity, 20(2), e13208. https://doi.org/10.1111/ijpo.13208
Tanveer, M., et al. (2025). Association of sleep duration with overweight and obesity among school-aged children and adolescents in Pakistan—An empirical cross-sectional study. Journal of Education and Health Promotion, 14(1), 43. https://doi.org/10.4103/jehp.jehp_1453_24
Tanveer, M., et al. (2025). Associations of parental support and involvement in sports with overweight and obesity among children and adolescents in Pakistan: An empirical cross-sectional study. Physical Activity Review, 13(1), 35–47. https://doi.org/10.16926/par.2025.13.04
Tanveer, M., et al. (2024). Association of physical activity and physical education with overweight and obesity among school-aged children and adolescents in Pakistan: An empirical cross-sectional study. Advances in Public Health, 2024, 5095049. https://doi.org/10.1155/2024/5095049
Tanveer, M., et al. (2024). Associations of school-level factors and school sport facility parameters with overweight and obesity among children and adolescents in Pakistan: An empirical cross-sectional study. Sports, 12(9), 235. https://doi.org/10.3390/sports12090235
Tanveer, M., et al. (2024). Association of nutrition behavior and food intake with overweight and obesity among school-aged children and adolescents in Pakistan: A cross-sectional study. AIMS Public Health, 11(3), 803–818. https://doi.org/10.3934/publichealth.2024040
Tanveer, M., et al. (2024). Community-level physical activity opportunities, safe and supportive environment factors, and their association with overweight and obesity among school-aged children and adolescents in Pakistan: A cross-sectional study. Kurdish Studies, 12(2), 6425–6432. https://doi.org/10.53555/ks.v12i2.2845
Tanveer, M., et al. (2024). Intrapersonal-level unhealthy behaviors (smoking, drinking alcohol, and tobacco use) and their association with body mass index among school-aged children and adolescents in Pakistan. Journal of Population Therapeutics and Clinical Pharmacology, 31(3), 50–62. https://doi.org/10.53555/jptcp.v31i3.4706
Tanveer, M., et al. (2024). Prevalence of body mass index and its association with interpersonal family-level factors among school-aged children and adolescents in Pakistan. Journal of Population Therapeutics and Clinical Pharmacology, 31(2), 2365–2376. https://doi.org/10.53555/jptcp.v31i2.4576
Tanveer, M., et al. (2022). The current prevalence of underweight, overweight, and obesity associated with demographic factors among Pakistan school-aged children and adolescents—An empirical cross-sectional study. International Journal of Environmental Research and Public Health, 19(18), 11619. https://doi.org/10.3390/ijerph191811619
Tanveer, M., et al. (2022). Community-level factors associated with body mass index among Pakistani school-aged adolescents. Pakistan Journal of Medical and Health Sciences, 16(9), 463–466. https://doi.org/10.53350/pjmhs22169463
Tanveer, M., et al. (2022). Parental health attitudes and knowledge factors associated with body mass index among Pakistani school-aged adolescents. Pakistan Journal of Medical and Health Sciences, 16(9), 479–482. https://doi.org/10.53350/pjmhs22169479
Tanveer, M., et al. (2022). Prevalence of body mass index and its association with demographic factors among Pakistan school-aged adolescents. Pakistan Journal of Medical and Health Sciences, 16(6), 212–215. https://doi.org/10.53350/pjmhs22166212
Tasawar, A., & Tanveer, M. (2024). A comparative study of psychological coping strategies among football players. Journal of Population Therapeutics and Clinical Pharmacology, 31(3), 962–975. https://doi.org/10.53555/jptcp.v31i3.5045
Roy, N., Tanveer, M., & Liu, Y.-H. (2022). Stress and coping strategies for international students in China during COVID-19 pandemic. International Research Journal of Education and Innovation, 3(1), 1–12. https://doi.org/10.53575/irjei.v3.01.1(22)1-12
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2025 MOHAMMAD AKHTAR NAWAZ GANJERA, M. ZAHID HAMEED KHAN, SAJJAD HAIDER, MATHEUS SANTOS DE SOUSA
This work is licensed under a Creative Commons Attribution 4.0 International License.
